

---

## CESSATION OF QUARTERLY REPORTING

---

Resonance Health Limited (**Resonance** or **Company**) (**ASX: RHT**) advises that ASX has confirmed the Company has sufficient positive net operating cash flow, for ASX to exercise its discretion to lift the requirement for the Company to lodge Appendix 4C quarterly reports, effective immediately.

Accordingly, the 'Appendix 4C Quarterly Activities & Cashflow Report' for the June 2026 quarter, released on 24 July 2026, will be the Company's final quarterly report unless otherwise advised by ASX. Resonance Health's next periodic report under Chapter 4 of ASX Listing Rules will be its preliminary financial report (Appendix 4E) due on 31 August 2026.

ASX confirmation follows the Company's sustained financial performance, including positive operating cash flow in all four quarters of FY26, full-year net positive operating cash inflow of \$2.9M, and a net cash position of \$2.3M at 30 June 2026, with Group revenue having grown from \$4M in FY23 to recent FY26 guidance of \$16M.

The Company will continue to keep the market informed of its performance and activities in accordance with its continuous disclosure obligations under ASX Listing Rule 3.1 and through its regular investor presentations released on ASX, ongoing announcements, Appendix 4D half-year, and Appendix 4E annual reports, and via its Annual General Meetings.

**Andrew Harrison, MD & CEO of the group noted:**

*"ASX's decision reflects where the business now sits – operating cash flow positive in every quarter of FY26, a growing net cash position, and revenue up from \$4M in FY23 to recent FY26 guidance of \$16M. Shareholders will continue to get the numbers that matter – at the half year, at the full year, and immediately in accordance with our continuous disclosure obligations."*

**Further Information:** <https://investors.resonancehealth.com>

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

**For further information:**

Andrew Harrison  
Managing Director  
E: [andrewh@resonancehealth.com](mailto:andrewh@resonancehealth.com)  
P: +61 8 9286 5300

---

## About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high-quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2\***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2\*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis. The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at [www.resonancehealth.com](http://www.resonancehealth.com) and to follow Resonance Health on LinkedIn.

## Disclaimer Forward Looking Statements

This announcement has been prepared by Resonance Health Ltd ("Resonance Health" or "Company") and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this release may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health's products and services.

These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.